References
- Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev.13(2), 137–177 (2007).
- Centorrino F, Fogarty KV, Sani G, Salvatore P, Cimbolli P, Baldessarini RJ. Antipsychotic drug use: McLean Hospital, 2002. Hum. Psychopharmacol.20(5), 355–358 (2005).
- Sernyak MJ, Rosenheck RA. Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006. Psychiatr. Serv.59(5), 567–569 (2008).
- Citrome L, Jaffe A, Levine J. How dosing of ziprasidone in a state hospital system differs from product labeling. J. Clin. Psychiatry70(7), 975–982 (2009).
- Citrome L. Using oral ziprasidone effectively: the food effect and dose–response. Adv. Ther.26(8), 739–748 (2009).
- Ketter TA, Wang PO. Longer-term management of bipolar disorders. In: Handbook of Diagnosis and Treatment of Bipolar Disorders. Ketter TA (Ed.). American Psychiatric Publishing, Inc., Washington, DC, USA 251–330 (2010).
- Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient’s clinical profile. CNS Spectr.9(10 Suppl. 11), 6–14 (2004).
- Miceli JJ, Glue P, Alderman J, Wilner K. The effect of food on the absorption of oral ziprasidone. Psychopharmacol. Bull.40(3), 58–68 (2007).
- Gandelman K, Alderman JA, Glue P et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open label, cross-over trial. J. Clin. Psychiatry70(1), 58–62 (2009).
- Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J. Clin. Psychiatry71(2), 130–137 (2010).
- Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J. Affect. Disord.109(3), 251–263 (2008).
- Suppes T, Vieta E, Liu S, Brecher M, Paulsson B; Trial 127 Investigators. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am. J. Psychiatry166(4), 476–488 (2009).
- Malhi GS, Adams D, Cahill CM, Dodd S, Berk M. The management of individuals with bipolar disorder: a review of the evidence and its integration into clinical practice. Drugs69(15), 2063–2101 (2009).
- Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med.13(9), 1102–1107 (2007).
Websites
- Pfizer, Inc. US Geodon® (ziprasidone HCl) and Geodon (ziprasidone mesylate) for injection, LAB-0272-0216.0 package insert. www.pfizer.com/files/products/uspi_geodon.pdf (Accessed 18 January 2010)
- Pfizer, Inc. Safety and maintenance of effect of ziprasidone plus a mood stabilizer in bipolar I disorder (manic or mixed). Study NCT00280566. http://clinicaltrials.gov/ct2/show/record/NCT00280566 (Accessed 18 January 2010)
- Pfizer, Inc. Protocol No. A1281137. www.clinicalstudyresults.org/documents/company-study_9018_0.pdf (Accessed 18 January 2010)
- Systematic Treatment Enhancement Program for Bipolar Disorder. www.stepbd.org (Accessed 18 January 2010)